|
|||||||
|
Fusion Protein:RET-FGFR3 |
Fusion Gene and Fusion Protein Summary |
 Fusion gene summary |
| Fusion partner gene information | Fusion gene name: RET-FGFR3 | FusionPDB ID: 73557 | FusionGDB2.0 ID: 73557 | Hgene | Tgene | Gene symbol | RET | FGFR3 | Gene ID | 5979 | 2261 |
| Gene name | ret proto-oncogene | fibroblast growth factor receptor 3 | |
| Synonyms | CDHF12|CDHR16|HSCR1|MEN2A|MEN2B|MTC1|PTC|RET-ELE1 | ACH|CD333|CEK2|HSFGFR3EX|JTK4 | |
| Cytomap | 10q11.21 | 4p16.3 | |
| Type of gene | protein-coding | protein-coding | |
| Description | proto-oncogene tyrosine-protein kinase receptor RetRET receptor tyrosine kinasecadherin family member 12cadherin-related family member 16proto-oncogene c-Retrearranged during transfectionret proto-oncogene (multiple endocrine neoplasia and medullary | fibroblast growth factor receptor 3FGFR-3fibroblast growth factor receptor 3 variant 4fibroblast growth factor receptor 3-Shydroxyaryl-protein kinasetyrosine kinase JTK4 | |
| Modification date | 20200322 | 20200313 | |
| UniProtAcc | RTL1 Main function of 5'-partner protein: 1358 | P22607 Main function of 5'-partner protein: FUNCTION: Tyrosine-protein kinase that acts as cell-surface receptor for fibroblast growth factors and plays an essential role in the regulation of cell proliferation, differentiation and apoptosis. Plays an essential role in the regulation of chondrocyte differentiation, proliferation and apoptosis, and is required for normal skeleton development. Regulates both osteogenesis and postnatal bone mineralization by osteoblasts. Promotes apoptosis in chondrocytes, but can also promote cancer cell proliferation. Required for normal development of the inner ear. Phosphorylates PLCG1, CBL and FRS2. Ligand binding leads to the activation of several signaling cascades. Activation of PLCG1 leads to the production of the cellular signaling molecules diacylglycerol and inositol 1,4,5-trisphosphate. Phosphorylation of FRS2 triggers recruitment of GRB2, GAB1, PIK3R1 and SOS1, and mediates activation of RAS, MAPK1/ERK2, MAPK3/ERK1 and the MAP kinase signaling pathway, as well as of the AKT1 signaling pathway. Plays a role in the regulation of vitamin D metabolism. Mutations that lead to constitutive kinase activation or impair normal FGFR3 maturation, internalization and degradation lead to aberrant signaling. Over-expressed or constitutively activated FGFR3 promotes activation of PTPN11/SHP2, STAT1, STAT5A and STAT5B. Secreted isoform 3 retains its capacity to bind FGF1 and FGF2 and hence may interfere with FGF signaling. {ECO:0000269|PubMed:10611230, ECO:0000269|PubMed:11294897, ECO:0000269|PubMed:11703096, ECO:0000269|PubMed:14534538, ECO:0000269|PubMed:16410555, ECO:0000269|PubMed:16597617, ECO:0000269|PubMed:17145761, ECO:0000269|PubMed:17311277, ECO:0000269|PubMed:17509076, ECO:0000269|PubMed:17561467, ECO:0000269|PubMed:19088846, ECO:0000269|PubMed:19286672, ECO:0000269|PubMed:8663044}. | |
| Ensembl transtripts involved in fusion gene | ENST ids | ENST00000340058, ENST00000355710, | ENST00000474521, ENST00000260795, ENST00000340107, ENST00000352904, ENST00000412135, ENST00000440486, ENST00000481110, |
| Fusion gene scores for assessment (based on all fusion genes of FusionGDB 2.0) | * DoF score | 9 X 6 X 4=216 | 6 X 11 X 9=594 |
| # samples | 9 | 9 | |
| ** MAII score | log2(9/216*10)=-1.26303440583379 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | log2(9/594*10)=-2.72246602447109 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | |
| Fusion gene context | PubMed: RET [Title/Abstract] AND FGFR3 [Title/Abstract] AND fusion [Title/Abstract] | ||
| Fusion neoantigen context | PubMed: RET [Title/Abstract] AND FGFR3 [Title/Abstract] AND neoantigen [Title/Abstract] | ||
| Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0) | RET(43612179)-FGFR3(1807285), # samples:1 | ||
| Anticipated loss of major functional domain due to fusion event. | RET-FGFR3 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF. RET-FGFR3 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF. RET-FGFR3 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF. RET-FGFR3 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF. | ||
| * DoF score (Degree of Frequency) = # partners X # break points X # cancer types ** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10) |
| Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez |
| Partner | Gene | GO ID | GO term | PubMed ID |
| Hgene | RET | GO:0030155 | regulation of cell adhesion | 21357690 |
| Hgene | RET | GO:0030335 | positive regulation of cell migration | 20702524 |
| Hgene | RET | GO:0033619 | membrane protein proteolysis | 21357690 |
| Hgene | RET | GO:0033630 | positive regulation of cell adhesion mediated by integrin | 20702524 |
| Hgene | RET | GO:0035860 | glial cell-derived neurotrophic factor receptor signaling pathway | 28953886 |
| Hgene | RET | GO:0043410 | positive regulation of MAPK cascade | 28846099 |
| Tgene | FGFR3 | GO:0008543 | fibroblast growth factor receptor signaling pathway | 8663044 |
| Tgene | FGFR3 | GO:0018108 | peptidyl-tyrosine phosphorylation | 11294897 |
| Tgene | FGFR3 | GO:0046777 | protein autophosphorylation | 11294897 |
| Four levels of functional features of fusion genes Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr10:43612179/chr4:1807285) - FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels. - How to search 1. Put your fusion gene symbol. 2. Press the tab key until there will be shown the breakpoint information filled. 4. Go down and press 'Search' tab twice. 4. Go down to have the hyperlink of the search result. 5. Click the hyperlink. 6. See the FGviewer result for your fusion gene. |
 |
| Retention analysis results of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features, are available here. |
| Fusion gene breakpoints across RET (5'-gene) * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
 |
| Fusion gene breakpoints across FGFR3 (3'-gene) * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
 |
Top |
Fusion Amino Acid Sequences |
| Fusion information from ORFfinder translation from full-length transcript sequence from FusionPDB. |
| Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | Seq length (transcript) | BP loci (transcript) | Predicted start (transcript) | Predicted stop (transcript) | Seq length (amino acids) |
| ENST00000355710 | RET | chr10 | 43612179 | + | ENST00000481110 | FGFR3 | chr4 | 1807285 | + | 4935 | 2516 | 232 | 3357 | 1041 |
| ENST00000355710 | RET | chr10 | 43612179 | + | ENST00000440486 | FGFR3 | chr4 | 1807285 | + | 5013 | 2516 | 232 | 3402 | 1056 |
| ENST00000355710 | RET | chr10 | 43612179 | + | ENST00000412135 | FGFR3 | chr4 | 1807285 | + | 5013 | 2516 | 232 | 3402 | 1056 |
| ENST00000355710 | RET | chr10 | 43612179 | + | ENST00000340107 | FGFR3 | chr4 | 1807285 | + | 5013 | 2516 | 232 | 3402 | 1056 |
| ENST00000355710 | RET | chr10 | 43612179 | + | ENST00000260795 | FGFR3 | chr4 | 1807285 | + | 5012 | 2516 | 232 | 3402 | 1056 |
| ENST00000355710 | RET | chr10 | 43612179 | + | ENST00000352904 | FGFR3 | chr4 | 1807285 | + | 5012 | 2516 | 232 | 3402 | 1056 |
| ENST00000340058 | RET | chr10 | 43612179 | + | ENST00000481110 | FGFR3 | chr4 | 1807285 | + | 4883 | 2464 | 180 | 3305 | 1041 |
| ENST00000340058 | RET | chr10 | 43612179 | + | ENST00000440486 | FGFR3 | chr4 | 1807285 | + | 4961 | 2464 | 180 | 3350 | 1056 |
| ENST00000340058 | RET | chr10 | 43612179 | + | ENST00000412135 | FGFR3 | chr4 | 1807285 | + | 4961 | 2464 | 180 | 3350 | 1056 |
| ENST00000340058 | RET | chr10 | 43612179 | + | ENST00000340107 | FGFR3 | chr4 | 1807285 | + | 4961 | 2464 | 180 | 3350 | 1056 |
| ENST00000340058 | RET | chr10 | 43612179 | + | ENST00000260795 | FGFR3 | chr4 | 1807285 | + | 4960 | 2464 | 180 | 3350 | 1056 |
| ENST00000340058 | RET | chr10 | 43612179 | + | ENST00000352904 | FGFR3 | chr4 | 1807285 | + | 4960 | 2464 | 180 | 3350 | 1056 |
| DeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated. |
| Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | No-coding score | Coding score |
| ENST00000355710 | ENST00000481110 | RET | chr10 | 43612179 | + | FGFR3 | chr4 | 1807285 | + | 0.001215983 | 0.998784 |
| ENST00000355710 | ENST00000440486 | RET | chr10 | 43612179 | + | FGFR3 | chr4 | 1807285 | + | 0.000537798 | 0.9994622 |
| ENST00000355710 | ENST00000412135 | RET | chr10 | 43612179 | + | FGFR3 | chr4 | 1807285 | + | 0.000537798 | 0.9994622 |
| ENST00000355710 | ENST00000340107 | RET | chr10 | 43612179 | + | FGFR3 | chr4 | 1807285 | + | 0.000537798 | 0.9994622 |
| ENST00000355710 | ENST00000260795 | RET | chr10 | 43612179 | + | FGFR3 | chr4 | 1807285 | + | 0.00053857 | 0.9994615 |
| ENST00000355710 | ENST00000352904 | RET | chr10 | 43612179 | + | FGFR3 | chr4 | 1807285 | + | 0.00053857 | 0.9994615 |
| ENST00000340058 | ENST00000481110 | RET | chr10 | 43612179 | + | FGFR3 | chr4 | 1807285 | + | 0.001168573 | 0.99883145 |
| ENST00000340058 | ENST00000440486 | RET | chr10 | 43612179 | + | FGFR3 | chr4 | 1807285 | + | 0.000521809 | 0.99947816 |
| ENST00000340058 | ENST00000412135 | RET | chr10 | 43612179 | + | FGFR3 | chr4 | 1807285 | + | 0.000521809 | 0.99947816 |
| ENST00000340058 | ENST00000340107 | RET | chr10 | 43612179 | + | FGFR3 | chr4 | 1807285 | + | 0.000521809 | 0.99947816 |
| ENST00000340058 | ENST00000260795 | RET | chr10 | 43612179 | + | FGFR3 | chr4 | 1807285 | + | 0.000522567 | 0.99947745 |
| ENST00000340058 | ENST00000352904 | RET | chr10 | 43612179 | + | FGFR3 | chr4 | 1807285 | + | 0.000522567 | 0.99947745 |
| Predicted full-length fusion amino acid sequences. For individual full-length fusion transcript sequence from FusionPDB, we ran ORFfinder and chose the longest ORF among all the predicted ones. |
Get the fusion protein sequences from here. |
| Fusion protein sequence information is available in the fasta format. >FusionGDB ID_FusionGDB isoform ID_FGname_Hgene_Hchr_Hbp_Henst_Tgene_Tchr_Tbp_Tenst_length(fusion AA) seq_BP |
Top |
Fusion Protein Breakpoint Sequences for RET-FGFR3 |
| +/-13 AA sequence from the breakpoints of the fusion protein sequences. |
| Hgene | Hchr | Hbp | Tgene | Tchr | Tbp | Length(fusion protein) | BP in fusion protein | Peptide |
Top |
Potential FusionNeoAntigen Information of RET-FGFR3 in HLA I |
| Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific. |
| Potential FusionNeoAntigen Information * We used NetMHCpan v4.1 (%rank<0.5) and deepHLApan v1.1 (immunogenic score>0.5) |
| Fusion gene | Hchr | Hbp | Tgene | Tchr | Tbp | HLA I | FusionNeoAntigen peptide | Binding score | Immunogenic score | Neoantigen start (at BP 13) | Neoantigen end (at BP 13) |
Top |
Potential FusionNeoAntigen Information of RET-FGFR3 in HLA II |
| Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific. |
| Potential FusionNeoAntigen Information * We used NetMHCIIpan v4.1 (%rank<0.5). |
| Fusion gene | Hchr | Hbp | Tgene | Tchr | Tbp | HLA II | FusionNeoAntigen peptide | Neoantigen start (at BP 13) | Neoantigen end (at BP 13) |
Top |
Fusion breakpoint peptide structures of RET-FGFR3 |
| 3D structures of the fusion breakpoint peptide of 14AA sequence that have potential fusion neoantigens * The minimum length of the amino acid sequence in RoseTTAFold is 14AA. Here, we predicted the 14AA fusion protein breakpoint sequence not the fusion neoantigen peptide, which is shorter than 14 AA. |
Top |
Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D of RET-FGFR3 |
| Virtual screening between 25 HLAs (from PDB) and FusionNeoAntigens * We used Glide to predict the interaction between HLAs and neoantigens. |
| HLA allele | PDB ID | File name | BPseq | Docking score | Glide score |
Top |
Vaccine Design for the FusionNeoAntigens of RET-FGFR3 |
| mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-Is. |
| Fusion gene | Hchr | Hbp | Tchr | Tbp | Start in +/-13AA | End in +/-13AA | FusionNeoAntigen peptide sequence | FusionNeoAntigen RNA sequence |
| mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-IIs. |
| Fusion gene | Hchr | Hbp | Tchr | Tbp | Start in +/-13AA | End in +/-13AA | FusionNeoAntigen peptide | FusionNEoAntigen RNA sequence |
Top |
Information of the samples that have these potential fusion neoantigens of RET-FGFR3 |
| These samples were reported as having these fusion breakpoints. For individual breakpoints, we checked the open reading frames considering multiple gene isoforms and chose the in-frame fusion genes only. Then, we made fusion protein sequences and predicted the fusion neoantigens. These fusion-positive samples may have these potential fusion neoantigens. |
| Cancer type | Fusion gene | Hchr | Hbp | Henst | Tchr | Tbp | Tenst | Sample |
Top |
Potential target of CAR-T therapy development for RET-FGFR3 |
| Predicted 3D structure. We used RoseTTAFold. |
| Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, to provide the retention of the transmembrane domain, we only show the protein feature retention information of those transmembrane features * Minus value of BPloci means that the break point is located before the CDS. |
| - In-frame and retained 'Transmembrane'. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
| Hgene | RET | chr10:43612179 | chr4:1807285 | ENST00000340058 | + | 12 | 19 | 636_657 | 761 | 1073.0 | Transmembrane | Helical |
| Hgene | RET | chr10:43612179 | chr4:1807285 | ENST00000355710 | + | 12 | 20 | 636_657 | 761 | 1115.0 | Transmembrane | Helical |
| Subcellular localization prediction of the transmembrane domain retained fusion proteins * We used DeepLoc 1.0. The order of the X-axis of the barplot is as follows: Entry_ID, Localization, Type, Nucleus, Cytoplasm, Extracellular, Mitochondrion, Cell_membrane, Endoplasmic_reticulum, Plastid, Golgi.apparatus, Lysosome.Vacuole, Peroxisome. Y-axis is the output score of DeepLoc. Clicking the image will open a new tab with a large image. |
| Hgene | Hchr | Hbp | Henst | Tgene | Tchr | Tbp | Tenst | DeepLoc result |
Top |
Related Drugs to RET-FGFR3 |
| Drugs used for this fusion-positive patient. (Manual curation of PubMed, 04-30-2022 + MyCancerGenome) |
| Hgene | Tgene | Drug | Source | PMID |
Top |
Related Diseases to RET-FGFR3 |
| Diseases that have this fusion gene. (Manual curation of PubMed, 04-30-2022 + MyCancerGenome) |
| Hgene | Tgene | Disease | Source | PMID |
| Diseases associated with fusion partners. (DisGeNet 4.0) |
| Partner | Gene | Disease ID | Disease name | # pubmeds | Source |
| Hgene | RET | C1833921 | Familial medullary thyroid carcinoma | 23 | CTD_human;GENOMICS_ENGLAND;ORPHANET;UNIPROT |
| Hgene | RET | C3888239 | HIRSCHSPRUNG DISEASE, SUSCEPTIBILITY TO, 1 | 16 | GENOMICS_ENGLAND;UNIPROT |
| Hgene | RET | C0025268 | Multiple Endocrine Neoplasia Type 2a | 15 | CTD_human;GENOMICS_ENGLAND;ORPHANET;UNIPROT |
| Hgene | RET | C1708353 | Hereditary Paraganglioma-Pheochromocytoma Syndrome | 12 | CLINGEN |
| Hgene | RET | C0025269 | Multiple Endocrine Neoplasia Type 2b | 10 | CTD_human;GENOMICS_ENGLAND;ORPHANET;UNIPROT |
| Hgene | RET | C0238463 | Papillary thyroid carcinoma | 3 | CTD_human;ORPHANET |
| Hgene | RET | C1275808 | Congenital central hypoventilation | 3 | CTD_human;GENOMICS_ENGLAND;UNIPROT |
| Hgene | RET | C1859049 | CCHS WITH HIRSCHSPRUNG DISEASE | 3 | CTD_human;ORPHANET |
| Hgene | RET | C0009402 | Colorectal Carcinoma | 2 | CTD_human;UNIPROT |
| Hgene | RET | C0009404 | Colorectal Neoplasms | 2 | CTD_human |
| Hgene | RET | C0019569 | Hirschsprung Disease | 2 | CTD_human |
| Hgene | RET | C0027662 | Multiple Endocrine Neoplasia | 2 | CTD_human;GENOMICS_ENGLAND |
| Hgene | RET | C0085758 | Aganglionosis, Colonic | 2 | CTD_human |
| Hgene | RET | C0266294 | Unilateral agenesis of kidney | 2 | ORPHANET |
| Hgene | RET | C1257840 | Aganglionosis, Rectosigmoid Colon | 2 | CTD_human |
| Hgene | RET | C3661523 | Congenital Intestinal Aganglionosis | 2 | CTD_human |
| Hgene | RET | C0006413 | Burkitt Lymphoma | 1 | CTD_human |
| Hgene | RET | C0031511 | Pheochromocytoma | 1 | CGI;CTD_human;GENOMICS_ENGLAND;UNIPROT |
| Hgene | RET | C0038220 | Status Epilepticus | 1 | CTD_human |
| Hgene | RET | C0040136 | Thyroid Neoplasm | 1 | CGI;CTD_human |
| Hgene | RET | C0151468 | Thyroid Gland Follicular Adenoma | 1 | CTD_human |
| Hgene | RET | C0206693 | Medullary carcinoma | 1 | CTD_human |
| Hgene | RET | C0238462 | Medullary carcinoma of thyroid | 1 | CGI;CTD_human |
| Hgene | RET | C0270823 | Petit mal status | 1 | CTD_human |
| Hgene | RET | C0311335 | Grand Mal Status Epilepticus | 1 | CTD_human |
| Hgene | RET | C0343640 | African Burkitt's lymphoma | 1 | CTD_human |
| Hgene | RET | C0393734 | Complex Partial Status Epilepticus | 1 | CTD_human |
| Hgene | RET | C0549473 | Thyroid carcinoma | 1 | CGI;CTD_human;UNIPROT |
| Hgene | RET | C0740340 | Amyloidosis, Familial | 1 | CTD_human |
| Hgene | RET | C0751522 | Status Epilepticus, Subclinical | 1 | CTD_human |
| Hgene | RET | C0751523 | Non-Convulsive Status Epilepticus | 1 | CTD_human |
| Hgene | RET | C0751524 | Simple Partial Status Epilepticus | 1 | CTD_human |
| Hgene | RET | C1257877 | Pheochromocytoma, Extra-Adrenal | 1 | CTD_human |
| Hgene | RET | C1609433 | Congenital absence of kidneys syndrome | 1 | CTD_human;GENOMICS_ENGLAND;ORPHANET |
| Hgene | RET | C3501843 | Nonmedullary Thyroid Carcinoma | 1 | CTD_human |
| Hgene | RET | C3501844 | Familial Nonmedullary Thyroid Cancer | 1 | CTD_human |
| Hgene | RET | C4721444 | Burkitt Leukemia | 1 | CTD_human |
| Tgene | FGFR3 | C0001080 | Achondroplasia | 13 | CLINGEN;CTD_human;GENOMICS_ENGLAND;ORPHANET;UNIPROT |
| Tgene | FGFR3 | C0410529 | Hypochondroplasia (disorder) | 10 | CTD_human;GENOMICS_ENGLAND;ORPHANET;UNIPROT |
| Tgene | FGFR3 | C1864436 | Muenke Syndrome | 9 | CTD_human;GENOMICS_ENGLAND;ORPHANET;UNIPROT |
| Tgene | FGFR3 | C1868678 | THANATOPHORIC DYSPLASIA, TYPE I (disorder) | 9 | CTD_human;GENOMICS_ENGLAND;UNIPROT |
| Tgene | FGFR3 | C2677099 | CROUZON SYNDROME WITH ACANTHOSIS NIGRICANS (disorder) | 7 | CTD_human;GENOMICS_ENGLAND;UNIPROT |
| Tgene | FGFR3 | C0005684 | Malignant neoplasm of urinary bladder | 6 | CGI;CTD_human;UNIPROT |
| Tgene | FGFR3 | C0005695 | Bladder Neoplasm | 4 | CGI;CTD_human |
| Tgene | FGFR3 | C1300257 | Thanatophoric dysplasia, type 2 | 4 | CTD_human;GENOMICS_ENGLAND;UNIPROT |
| Tgene | FGFR3 | C1864852 | CATSHL syndrome | 4 | CTD_human;GENOMICS_ENGLAND;ORPHANET;UNIPROT |
| Tgene | FGFR3 | C2674173 | Achondroplasia, Severe, With Developmental Delay And Acanthosis Nigricans | 3 | CTD_human;GENOMICS_ENGLAND;ORPHANET;UNIPROT |
| Tgene | FGFR3 | C0265269 | Lacrimoauriculodentodigital syndrome | 2 | CTD_human;GENOMICS_ENGLAND;ORPHANET;UNIPROT |
| Tgene | FGFR3 | C0007138 | Carcinoma, Transitional Cell | 1 | CTD_human |
| Tgene | FGFR3 | C0008924 | Cleft upper lip | 1 | CTD_human |
| Tgene | FGFR3 | C0008925 | Cleft Palate | 1 | CTD_human |
| Tgene | FGFR3 | C0014544 | Epilepsy | 1 | GENOMICS_ENGLAND |
| Tgene | FGFR3 | C0014547 | Epilepsies, Partial | 1 | GENOMICS_ENGLAND |
| Tgene | FGFR3 | C0022603 | Seborrheic keratosis | 1 | UNIPROT |
| Tgene | FGFR3 | C0026764 | Multiple Myeloma | 1 | CGI;CTD_human |
| Tgene | FGFR3 | C0036631 | Seminoma | 1 | CTD_human |
| Tgene | FGFR3 | C0039743 | Thanatophoric Dysplasia | 1 | CTD_human |
| Tgene | FGFR3 | C0152423 | Congenital small ears | 1 | GENOMICS_ENGLAND |
| Tgene | FGFR3 | C0206726 | gliosarcoma | 1 | ORPHANET |
| Tgene | FGFR3 | C0221356 | Brachycephaly | 1 | ORPHANET |
| Tgene | FGFR3 | C0265529 | Plagiocephaly | 1 | ORPHANET |
| Tgene | FGFR3 | C0334082 | NEVUS, EPIDERMAL (disorder) | 1 | CTD_human;UNIPROT |
| Tgene | FGFR3 | C0334588 | Giant Cell Glioblastoma | 1 | ORPHANET |
| Tgene | FGFR3 | C0406803 | Syringocystadenoma Papilliferum | 1 | GENOMICS_ENGLAND |
| Tgene | FGFR3 | C1336708 | Testicular Germ Cell Tumor | 1 | CTD_human;UNIPROT |
| Tgene | FGFR3 | C1837218 | Cleft palate, isolated | 1 | CTD_human |
| Tgene | FGFR3 | C4048328 | cervical cancer | 1 | CTD_human;UNIPROT |
Copyright 2023-PresentThe University of Texas Health Science Center at Houston (UTHealth)
Web File Viewing | Emergency Information
Campus Carry|Site Policies